Friday, April 26, 2019 5:36:44 PM
Some figures to help out those who say this is worth nothing
If I remember right the report* said $400 exclusive market year one and adding $100 million per year to 2027 where it is estimated to be $1.3 billion. As we're not in year 1 since we have no drug - yet, I moved it to 2020 as year one with, the advance in market going up as per the rationale of the report. (All figures in USD not CD unless specified)
You can adjust the start time or years with completion but I'm just trying to show what kind of money we're talking about here.
2018 $
2019 $
2020 $ 600,000,000
2021 $ 700,000,000
2022 $ 800,000,000
2023 $ 900,000,000
2024 $1,000,000,000
2025 $1,100,000,000
2026 $1,200,000,000
2027 $1,300,000,000
Total $7,600,000,000 ($10,133,000,000 CD) over 8 years or $1.4 billion($1.86 CD) per year average. I'm no rocket scientist but with an exclusive market like that and present shares outstanding of 304 million at cap of $18 million, assuming fifty percent profit brings us to a profit of $12.5 per share ($16.6 CD) over that period.
Or, if it's 75% profit then share profit is $18.75 ($25 CD) Average over 8 years and it's $2.34 ($3.12 CD) per share.
In any case, if anybody is worried about dilution, as long as it's helping us get to the start line it's fine with me.
Of course, what do I know, I might be missing something here or, maybe missing everything. Any experts want to chime in?
*"The commercial opportunity for Kalytera’s CBD products for the prevention and treatment of GVHD is large. According to the January 2018 Market Forecast Report by DelveInsight Perspective, the potential market for a successful product for prevention and treatment of GVHD in the 7 major jurisdictions (the U.S., Germany, France, Italy, Spain, the U.K. and Japan) is estimated to be more than USD $408 million in 2018, and could grow to approximately USD $1.3 billion by 2027."
Read more at https://stockhouse.com/companies/bullboard?symbol=kaltf&postid=29590536#dfG0gd8Md272guYF.99
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM